J&J's Janssen Launches EXPLORER Research Program

Janssen Research & Development, LLC (Janssen) today announced the launch of EXPLORER, a comprehensive, global research program for XARELTO^® (rivaroxaban), an oral anticoagulant. The program includes studies that will evaluate XARELTO^® for investigational use in patients with chronic heart failure and in those with coronary artery disease or peripheral artery disease. XARELTO^® does not require routine blood monitoring, and with approvals for six distinct uses, it has the broadest indication profile of any of the newer oral anticoagulants in the market today. XARELTO^® is approved in the U.S. for reducing the risk of strokes in patients with nonvalvular atrial fibrillation; as a treatment for deep vein thrombosis and pulmonary embolism and to prevent recurrence of these events; and for reducing the risk of blood clots in the legs and lungs of people who have had hip or knee replacement surgery. The extensive program of clinical trials evaluating XARELTO^® makes the compound the most studied oral, Factor Xa inhibitor in the world today. By the time of its completion, more than 100,000 patients will have participated in the XARELTO^® clinical development program.